Charles Schwab Investment Management Inc. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Charles Schwab Investment Management Inc. grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,783,177 shares of the biopharmaceutical company's stock after purchasing an additional 9,780 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.40% of Halozyme Therapeutics worth $85,254,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of HALO. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $69,000. Farther Finance Advisors LLC grew its position in Halozyme Therapeutics by 173.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 1,028 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Trading Up 2.0 %

HALO stock traded up $1.21 during midday trading on Friday, hitting $62.27. The stock had a trading volume of 1,042,419 shares, compared to its average volume of 1,312,358. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The business has a fifty day moving average price of $56.76 and a two-hundred day moving average price of $54.76. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The firm has a market cap of $7.67 billion, a P/E ratio of 18.15, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now owns 33,611 shares in the company, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 in the last quarter. Company insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.